Psoriasis

While noting that providers and their patients should be aware of the potential risk, the researchers underscored that the risk of new-onset psoriasis due to tumor necrosis factor-α inhibitor (TNFi) treatment appears to be rare and that strategies do not need to change for patients with immune-mediated inflammatory diseases such as inflammatory bowel disease (IBD) and/or rheumatoid arthritis (RA).

The findings add to previous research on similar outcomes between psoriasis and cardiovascular disease, using a Mendelian randomization study.

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses the need for increased research and awareness on intertriginous disease in psoriasis.

The real-life findings showed that treatment with brodalumab improved health-related quality of life (HRQOL) for patients but itching prevented complete improvement.

Dermatologists spend less time face-to-face with Asian patients with psoriasis compared with patients of other races and ethnicities, despite Asian patients frequently experiencing more severe cases of psoriasis.

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, speaks about disease manifestations, comorbidities, and other factors to consider in the management of psoriasis.

According to the investigator, these findings further support psoriasis as a systemic inflammatory disease.

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discussed key factors associated with poor behavioral health issues and quality of life among patients with psoriasis.

Despite incidence of psoriasis decreasing, older populations in Taiwan have a higher risk of developing psoriasis and psoriatic arthritis, according to a recent study.

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses findings of a recent survey exploring the emotional burden of plaque psoriasis and unmet needs related to current topical treatments.

Drug survival rates of biologics in patients with psoriasis were shown to be associated with their effectiveness and safety profiles, in which incidence of psoriatic arthritis, nail involvement, and other factors were indicated as effect modifiers.

A Mendelian randomization study found that there appears to be a causal relationship between inflammatory bowel disease (IBD) and psoriasis.

Researchers found no evidence of increased risk for severe COVID-19 among children receiving biologic therapies for their psoriasis.

Patients with psoriatic arthritis (PsA) exhibited a higher prevalence of cardiovascular risk factors and events vs the general population, including atherothrombotic disease.

An analysis of biologic drug use patterns in patients with psoriasis from Tuscany, Italy, associated etanercept with the highest frequency of switching to other biologics; secukinumab and ustekinumab were linked with the lowest risk.

A systematic review found that skin clearance, symptom control, and treatment safety were among the highest expected outcomes of treatment for patients with psoriasis.

Sex and age were associated with clinical characteristics of geriatric psoriasis, including type and location of disease, therapeutic considerations, and risk of comorbid nail involvement and psoriatic arthritis.

Efficacy of biologics was observed in both men and women with psoriasis, although female patients reported a greater impact from the disease on quality of life (QOL) and lower treatment satisfaction.

Risk of ectopic pregnancy, the leading cause of maternal morbidity and mortality in the first trimester of pregnancy, was significantly associated with psoriasis in Danish women, especially those with moderate to severe disease.

US adult outpatients with psoriasis have a greater risk of developing nonalcoholic fatty liver disease compared with those without the skin condition.

Real-world patients with moderate to severe plaque psoriasis who had experienced prior biologic failure demonstrated significant improvement and an adequate safety profile with risankizumab treatment.

Real-world patients with psoriasis demonstrated significant improvement in difficult-to-treat scalp, nail, palmoplantar, and genital disease manifestations with the IL-23 inhibitor tildrakizumab.

Significantly greater persistence, adherence, and time on monotherapy was achieved with the use of ixekizumab vs the biologics adalimumab, etanercept, secukinumab, and ustekinumab, in the treatment of moderate to severe psoriasis.

Patients with psoriatic disease who live in low-income countries exhibited the highest disease activity and impact despite similar usage of biologic drugs to that of higher-income areas.

Bimekizumab demonstrated a favorable long-term safety profile for the treatment of moderate to severe psoriasis, aside from an increased incidence of mild to moderate oral candidiasis that was also observed with short-term exposure.

An overlapping comorbidity profile was observed among patients with plaque psoriasis and palmoplantar pustulosis, although risks of certain comorbid conditions varied between the 2 groups.

A significantly greater risk of cardiovascular events was observed among a multiethnic Brazilian population of patients with psoriasis and psoriatic arthritis vs controls, in which those in the sixth decade of life had the highest risk.

Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America, discussed next steps in the evaluation of tildrakizumab for the treatment of psoriasis.

Lifestyle behaviors, such as body mass index and smoking, were shown to have a greater predictive impact regarding development of psoriasis compared with genetic predisposition.

Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America, discussed findings of 2 phase 4 real-world studies on tildrakizumab, which showed that patients achieved significant improvement in severity and quality of life by week 4 of treatment.